Krebs Biochemicals and Industries Ltd (KREB)

Currency in INR
76.37
-0.24(-0.31%)
Closed·

KREB Financial Summary

Key Ratios

P/E Ratio-6
Price/Book-1.11
Debt / Equity-145.11%
Return on Equity20.3%
Dividend Yield0.00%
EBITDA-143.21M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Earnings

Latest Release
May 20, 2025
EPS / Forecast
-3.83 / --
Revenue / Forecast
64.39M / --
EPS Revisions
Last 90 days

FAQ

What were Krebs Biochemicals's earnings for the latest quarter?

The Krebs Biochemicals EPS (TTM) is -12.49. Krebs Biochemicals reported sales of 61.01, net income of -82.68, and EPS of -3.83 for the latest quarter.

What was Krebs Biochemicals's net income for the latest quarter?

Krebs Biochemicals's net income for the latest quarter was -82.68.

How did Krebs Biochemicals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 114.67 in the previous quarter to 61.01 in the latest quarter, and net income moved from -77.39 to -82.68 compared to the previous quarter.

What is Krebs Biochemicals's net profit margin on a TTM basis?

Krebs Biochemicals's trailing twelve months (TTM) net profit margin is -62.20%.

How does Krebs Biochemicals's debt to equity ratio compare to industry standards?

Krebs Biochemicals's total debt-to-equity ratio is -145.11%.

What is Krebs Biochemicals's return on investment on a TTM basis?

Krebs Biochemicals's trailing twelve months (TTM) return on investment (ROI) is 20.30%.

What were Krebs Biochemicals's total assets and liabilities in the latest quarter?

As of the latest quarter, Krebs Biochemicals reported total assets of 1,690.36 million and total liabilities of 1,035.26 million.

How has Krebs Biochemicals's total revenue grown this year?

Krebs Biochemicals's total revenue was 114.67 in the previous quarter and 61.01 in the latest quarter.

What is Krebs Biochemicals's gross margin on a TTM basis?

Krebs Biochemicals's trailing twelve months (TTM) gross margin is 87.17%.

What was Krebs Biochemicals's revenue per share for the latest quarter?

Krebs Biochemicals's revenue per share for the latest quarter was 296.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.